Business Wire

Lattice Reinvents the Low Power, General-Purpose FPGA with New Certus-NX

24.6.2020 23:00:00 EEST | Business Wire | Press release

Share

Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today launched the new Lattice Certus™-NX family of FPGAs. The devices lead the general-purpose FPGA market in I/O density, delivering up to twice the I/O density per mm2 in comparison to similar competing FPGAs, and provide best-in-class power savings, small size, reliability, instant-on performance, and support fast PCI Express (PCIe) and Gigabit Ethernet interfaces to enable data co-processing, signal bridging, and system control. Certus-NX FPGAs target a range of applications, from data processing in automated industrial equipment to system management in communications infrastructure. The Certus-NX devices are the second family of FPGAs developed on the Lattice Nexus™ platform, the industry’s first low power FPGA platform using 28 nm FD-SOI process technology. With the launch of Certus-NX, Lattice marks the release of the second device family developed under Lattice’s new product development strategy in just six months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005722/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The new Certus™-NX Low Power, General Purpose FPGA from Lattice Semiconductor (Photo: Business Wire)

“Certus-NX delivers unique and innovative capabilities that set it apart,” said Linley Gwennap, Principal Analyst at The Linley Group. “Compared to competing FPGAs of similar gate counts, Lattice offers a much smaller package, greater I/O density, and lower power.”

“Thanks to innovations at the system, architecture, and circuit level in our Lattice Nexus development platform, we are releasing new products at a faster pace and giving our customers more options to choose from as they evaluate the performance and power needs of their applications,” said Gordon Hands, Director of Product Marketing, Lattice Semiconductor. “Certus-NX has clearly reset expectations for what developers should look for in general-purpose FPGAs by providing a compelling blend of parallel processing performance and flexible I/O support that enables creative new device designs.”

Technology trends like industrial automation and 5G have developers across markets looking to add processing and connectivity to applications that operate at the network Edge. To successfully support these trends, devices require low power processing hardware with support for popular interfaces like PCIe and Gigabit Ethernet. Device developers also need easy-to-use development platforms from a single source that provide the hardware, software, and IP they need to get products to market quickly.

“As an FPGA-centric design house, we’re seeing increasing adoption of serial protocols like PCIe and Gigabit Ethernet for chip-to-chip connectivity in many end applications, including 5G and IoT systems,” said Sanjeev Kumar, CEO, Logic Fruit Technologies. “The latest generation of FPGAs by Lattice, Certus-NX, supports these standards and provides a high density of I/Os while keeping power consumption and overall device footprint in check. These FPGAs will allow us to rapidly adapt to the challenging and evolving connectivity and performance needs of our customers.”

Key features of the Lattice Certus-NX FPGA family include:

  • Up to 3x smaller form factor – Certus-NX FPGAs easily fit into compact designs with minimal impact on overall design footprint. For example, Certus-NX FPGAs can enable a complete PCIe solution with a size of only 36 mm2. Even when using the smallest package available in the family, Certus-NX FPGAs deliver up to twice the I/O density per mm2 in comparison to similar competing FPGAs to enable greater design flexibility and robust support for bridging applications.
  • Robust I/O interfacing capability – Certus-NX developers will have access to Lattice’s extensive IP library. Notable IP blocks available on Certus-NX include:
    • 1.5 Gbps differential I/O with performance that is up to 70 percent higher than competing FPGAs.
    • 5 Gbps PCIe, 1.5 Gbps SGMII, and 1066 Mbps DDR3. Developers can test these IP blocks on Certus-NX development boards for the fast implementation of interfaces commonly used in Certus-NX FPGAs’ target applications.
  • Robust authentication and encryption – To secure the devices’ bitstream against unauthorized access/alteration/copying, Certus-NX FPGAs support AES-256 with ECDSA authentication to protect devices throughout their lifecycles. Currently, Certus-NX devices are the smallest FPGAs on the market to support ECDSA.

  • Up to 4x lower power consumption – Certus-NX FPGAs use a programmable back bias to enable user-selectable high performance or low power operating modes, depending on the needs of their application. The devices can provide power consumption up to 4x lower than similar FPGAs.
  • Instant-on performance – The devices also offer ultra-fast device configuration from SPI memory that is up to 12x faster than similar competing FPGAs, with individual I/Os able to configure in just 3 ms, and full-device startup in only 8-14 ms depending on device capacity.
  • High reliability – Reliable performance is key for safety-critical industrial and automotive applications where devices must perform as expected to avoid damage/injury. Certus-NX FPGAs offer up to 100 times better soft-error rate (SER) performance than similar FPGAs. Certus-NX FPGAs are temperature-rated for use in industrial applications. They also support ECC and SEC in hardware.
  • Ease of use/design – Certus-NX FPGAs support Lattice Radiant® software, an easy-to-use, unified FPGA design environment that integrates best-in-class tools and features to help users develop their applications quickly and efficiently.

Lattice has already shipped sample devices to select customers. For more information, please visit http://www.latticesemi.com/Certus-NX.

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive, and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world.

For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, Weibo or Youku.

Lattice Semiconductor Corporation, Lattice Semiconductor (& design) and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA CONTACT:
Bob Nelson
Lattice Semiconductor
408-826-6339
Bob.Nelson@latticesemi.com

INVESTOR CONTACT:
Rick Muscha
Lattice Semiconductor
408-826-6000
Rick.Muscha@latticesemi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye